EUA is still very much on the table for Moderate.
Post# of 148181
With the criteria established that just Moderate, > 4 clinical are being examined, with NEWS2, viremia, and a host of Cytokine markers are the endpoints, along with clinical improvement, any indication of effecacy in a Moderate PIII trial will justify EUA for that population. Neither the US nor UK would overlook that.
2. Jury is out... depends on how clear the interim results are. Sounds like the UK is considering it.
3-6: check
7: ....
8: not if it doesn't pass
S/C is the next catalyst. Another Buying Opp.